Make Success More Certain
Contribute to Better Health All Over the World
Founded in 2007, Bora Pharmaceuticals is a leading pharmaceutical services provider. With our unique dual-engine business model combining CDMO (Contract Development and Manufacturing Organization) capabilities with drug development and commercialization, we help our partners to accelerate time-to-market and improve access. By continuously investing in talent, manufacturing, commercial capabilities, and expanding into biologics, Bora is committed to driving innovation and long-term growth.
- What We Do
Our Business
We offer next-level delivery excellence through a combined focus on maximizing manufacturing efficiency, while never compromising on quality.
- Who We Are
WE ARE BORA
We’re setting new standards in pharma and CDMO, driven by our commitment quality, efficiency, and a mission to make success more certain.
- Careers
WORK WITH US
Bora empowers global teams to
grow professionally, united by
shared purpose.
Milestones
2007
Bora Pharmaceuticals was founded by Bobby Sheng with a mission of “Contributing to Better Health All Over the World” and to become a world-leading pharmaceutical services company.
2007 - 2012
Bora emerged as a development-scale CDMO and top CNS / neurology product distributor in Taiwan, with Lexapro and Lendormin as key market blockbusters.
2013-2016
Acquired Eisai’s Tainan facility, marking Bora’s first scalable CDMO move. Continued investing in R&D and expanding via in-licensed pharmaceutical products.
2017
Bora completed IPO on Taipei Stock Exchange and acquires Taiwan based Yuta Health.
2018-2020
Expanded small molecule CDMO through acquisitions in Zhunan, Taiwan (ex-Impax/Amneal), and Mississauga, Canada (ex-GSK). Successfully integrated the Canadian site during COVID-19.
2022-2023
• Bora entered large molecule sector, acquired Eden Biologics and established Bora Biologics.
• Merged with Taiwan’s complex generics leader TWi.
2023
• Bora becomes major shareholder of SunWay Biotech.
• Bora listed on Taiwan Stock Exchange.
• Launched Dexlansoprazole DR in the U.S., named a top 2023 launch by IQVIA.
2024
Completed the acquisition of Upsher-Smith and a Maryland-based site (ex-Emergent) to drive business transformation, and made a strategic investment into Tanvex to provide global biomanufacturing services.
2025
Bora completed strategic investment into Tanvex, a Biosimilar company for CDMO endeavors.
NEWS CENTER

Business
Bora Wins Prestigious CDMO Leadership Awards TAIPEI, TAIWAN, March 20, 2025 – Bora Pharmaceuticals Co., Ltd. (“Bora” or “the

Investors
43rd Annual J.P. Morgan Healthcare Conference Bora Pharmaceuticals has been invited to participate in the prestigious J.P. Morgan Healthcare Conference

Community
April 11 is World Parkinson’s Day. To mark the occasion, the Center for Parkinson and Movement Disorders at National Taiwan

People
Bora Appoints J.D. Mowery As First Division President Of Its CDMO Business TAIPEI, TAIWAN, October 3, 2024 – Bora

Events
43rd Annual J.P. Morgan Healthcare Conference Bora Pharmaceuticals has been invited to participate in the prestigious J.P. Morgan Healthcare Conference